Investment in Jiaxing Pharmaceutical Factory and Acquisition of Singapore Assets Totaling 17 Billion Yuan

An innovative pharmaceutical company from Jiaxing expands its overseas presence. On April 8, the Chairman of Yunding Xinyao, Wu Yifang, announced the intended acquisition of a Singaporean company with a total transaction price of approximately 1.7 billion RMB. The target of this acquisition is a subsidiary of Hesen Biology. Yunding Xinyao revealed that post-closing the deal, they would obtain 14 mature chronic disease products and a commercial team in the Asia-Pacific region. By 2025, Yunding Xinyao’s revenue is projected to surpass 1.7 billion RMB, more than doubling the current figure. The company’s new target is to surpass 15 billion RMB…